2024
Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox model
2023
Excess Mortality Among Patients in the Veterans Affairs Health System Compared With the Overall US Population During the First Year of the COVID-19 Pandemic
Weinberger D, Rose L, Rentsch C, Asch S, Columbo J, King J, Korves C, Lucas B, Taub C, Young-Xu Y, Vashi A, Davies L, Justice A. Excess Mortality Among Patients in the Veterans Affairs Health System Compared With the Overall US Population During the First Year of the COVID-19 Pandemic. JAMA Network Open 2023, 6: e2312140. PMID: 37155169, PMCID: PMC10167568, DOI: 10.1001/jamanetworkopen.2023.12140.Peer-Reviewed Original ResearchConceptsGeneral US populationVA health care systemHealth care systemComprehensive medical careOverall US populationRate of deathVA populationUS populationDeath rateCohort studyExcess mortalityCare systemCOVID-19 pandemicMedical careVeterans Affairs Health Care SystemVeterans Affairs Health SystemHealth systemVA health systemFirst yearVA health careStandardized mortality rateAdult age groupsVA enrolleesMAIN OUTCOMEGeneral population
2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, Mansfield KE, Bechman K, Yates M, Brown J, Schultze A, Norton S, Walker AJ, Morton CE, Harrison D, Bhaskaran K, Rentsch CT, Williamson E, Croker R, Bacon S, Hickman G, Ward T, Davy S, Green A, Fisher L, Hulme W, Bates C, Curtis HJ, Tazare J, Eggo RM, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson LA, Mathur R, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Lees CW, Evans SJW, Goldacre B, Smith CH, Langan SM. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. The Lancet Rheumatology 2022, 4: e490-e506. PMID: 35698725, PMCID: PMC9179144, DOI: 10.1016/s2665-9913(22)00098-4.Peer-Reviewed Original ResearchImmune-mediated inflammatory diseasesCOVID-19-related deathsSevere COVID-19 outcomesImmune-modifying therapiesCritical care admissionInflammatory diseasesCOVID-19 outcomesImmune-modifying drugsHospital admissionGeneral populationCare admissionHazard ratioStandard systemic therapyStandard systemic treatmentSevere COVID-19Primary care recordsPrimary care dataNon-white ethnic groupsCohort studySystemic therapySystemic treatmentCox regressionPrescription dataCare recordsWhite ethnic groupRates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform
Collaborative T, Tazare J, Walker A, Tomlinson L, Hickman G, Rentsch C, Williamson E, Bhaskaran K, Evans D, Wing K, Mathur R, Wong A, Schultze A, Bacon S, Bates C, Morton C, Curtis H, Nightingale E, McDonald H, Mehrkar A, Inglesby P, Davy S, MacKenna B, Cockburn J, Hulme W, Warren-Gash C, Bhate K, Nitsch D, Powell E, Mulick A, Forbes H, Minassian C, Croker R, Parry J, Hester F, Harper S, Eggo R, Evans S, Smeeth L, Douglas I, Goldacre B. Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform. Wellcome Open Research 2022, 7: 142. PMID: 37362009, PMCID: PMC10285340, DOI: 10.12688/wellcomeopenres.17735.1.Peer-Reviewed Original ResearchDeep vein thrombosisCOVID-19 patientsHigh riskGeneral populationOpenSAFELY platformPulmonary embolismMyocardial infarctionCOVID-19Type 2 diabetes mellitus diagnosisSerious clinical outcomesPrimary care recordsDescriptive cohort studyCOVID-19 populationRisk of outcomesDiabetes mellitus diagnosisAge/sexMajority of outcomesPulmonary complicationsComparator cohortCohort studyIschemic strokeVein thrombosisHeart failureClinical outcomesAdverse outcomesComparison of methods for predicting COVID-19-related death in the general population using the OpenSAFELY platform
Williamson E, Tazare J, Bhaskaran K, McDonald H, Walker A, Tomlinson L, Wing K, Bacon S, Bates C, Curtis H, Forbes H, Minassian C, Morton C, Nightingale E, Mehrkar A, Evans D, Nicholson B, Leon D, Inglesby P, MacKenna B, Davies N, DeVito N, Drysdale H, Cockburn J, Hulme W, Morley J, Douglas I, Rentsch C, Mathur R, Wong A, Schultze A, Croker R, Parry J, Hester F, Harper S, Grieve R, Harrison D, Steyerberg E, Eggo R, Diaz-Ordaz K, Keogh R, Evans S, Smeeth L, Goldacre B. Comparison of methods for predicting COVID-19-related death in the general population using the OpenSAFELY platform. Diagnostic And Prognostic Research 2022, 6: 6. PMID: 35197114, PMCID: PMC8865947, DOI: 10.1186/s41512-022-00120-2.Peer-Reviewed Original ResearchCOVID-19-related deathsInfection prevalenceOpenSAFELY platformGeneral populationNational Statistics mortality dataNumber of comorbiditiesRisk prediction toolsAbsolute risk estimationStatistics mortality dataAbsolute risk estimatesCase-cohort sampleRisk prediction modelTarget populationElectronic health record systemsPrimary careCOVID-19 casesGeneral practiceEmergency careHealth record systemsLocal infection prevalenceNHS EnglandBasic demographicsPrevalenceMortality dataRisk estimatesOverall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
Bhaskaran K, Rentsch CT, Hickman G, Hulme WJ, Schultze A, Curtis HJ, Wing K, Warren-Gash C, Tomlinson L, Bates CJ, Mathur R, MacKenna B, Mahalingasivam V, Wong A, Walker AJ, Morton CE, Grint D, Mehrkar A, Eggo RM, Inglesby P, Douglas IJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Parry J, Hester F, Harper S, Evans SJ, Bacon S, Smeeth L, Goldacre B. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLOS Medicine 2022, 19: e1003871. PMID: 35077449, PMCID: PMC8789178, DOI: 10.1371/journal.pmed.1003871.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCOVID-19 hospitalisationGeneral population controlsCOVID-19 groupCOVID-19 survivorsHospital admissionHigh riskInfluenza hospitalisationsCause mortalityCohort studyInfluenza patientsPrimary careGeneral populationInitial infectionAcute coronavirus disease 2019Lower respiratory tract infectionsSevere COVID-19 outcomesLong-term adverse outcomesCOVID-19 hospital admissionsSpecific causesPopulation controlsCause-specific hospitalisationRespiratory tract infectionsCause-specific outcomesPotential risk factors
2021
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Forbes H, Eggo RM, Parry J, Hester F, Harper S, Evans SJ, Smeeth L, Douglas IJ, Goldacre B, Collaborative T. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals Of The Rheumatic Diseases 2021, 80: 943-951. PMID: 33478953, PMCID: PMC7823433, DOI: 10.1136/annrheumdis-2020-219517.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsPrescribed non-steroidal anti-inflammatory drugsRheumatoid arthritis/osteoarthritisArthritis/osteoarthritisCurrent NSAID usersMultivariable-adjusted modelsAnti-inflammatory drugsNSAID prescriptionsNSAID usersGeneral populationCOVID-19Risk of deathNational Health Service EnglandRoutine therapeutic useRoutine clinical dataCohort studyCurrent useCox regressionClinical dataCohort analysisLower riskEvidence of differencesDeath dataTherapeutic useDeath